State of the art of surgery in advanced epithelial ovarian cancer

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Hacker, N F ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; METASTASIS; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; VIDEO ASSISTED THORACOSCOPIC SURGERY;

FEMALE; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84888260278     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt465     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Baldwin LA, Huang B, Miller RW et al. Ten-Year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012; 120: 612-618.
3. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953.
4. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Natl Cancer Inst Monogr 1975; 42: 101-104.
5. Griffiths CT, Parker LM, Fuller AF, Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 235-240.
6. Hacker NF, Berek JS, Lagasse LD et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-420.
7. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733.
8. Farias-Eisner R, Teng F, Oliveira M et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994; 55: 108-110.
9. Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-166.
10. Eisenkop SM, Friedman RL, Wang H-J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69: 103-108.
11. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
12. Du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009; 115: 1234-1244.
13. Aletti GD, Gostout BS, Podratz KC et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006; 100: 33-37.
14. Scarbelli C, Gallo A, Zarrelli A et al. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol 1995; 56: 328-337.
15. Du Bois A, Reuss A, Harter P et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicentre trials. J Clin Oncol 2010; 28: 1733-1739.
16. Chang S-J, Bristow RE, Ryu H-S. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecol Oncol 2012; 126: 381-386.
17. Rouzier R, Bergzoll C, Brun J-L et al. The role of lymph node resection in ovarian cancer: an analysis of Surveillance, Epidemiology, and End Results (SEER) database. BJOG 2010; 117: 1451-1458.
18. Benedetti-Panici PB, Maggioni A, Hacker NF et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97: 560-566.
19. Eisenkop SM. Thoracoscopy for the management of advanced epithelial ovarian cancer-a preliminary report. Gynecol Oncol 2002; 84: 315-320.
20. Chi DS, Abu-Rustum NR, Sonoda Y et al. The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol 2004; 94: 307-311.
21. Klar M, Farthmann J, Bossart M et al. Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer. Gynecol Oncol 2012; 126: 397-402.
22. Hynninen J, Auranen A, Carpen O et al. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol 2012; 126: 64-68.
23. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103: 1070-1076.
24. Skipper HE. Adjuvant chemotherapy. Cancer 1978; 41: 936-940.
25. Kang S, Nam B-H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 2009; 16: 2315-2320.
26. Du Bois A, Marth C, Pfisterer J et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer 2012; 22: 182-185.
27. Chi DS, Musa F, Dao F et al. An analysis of patients with bulky advanced stage ovarian, tubal, or peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012; 124: 10-14.
28. Luyckx M, Leblanc E, Filleron T et al. Maximal cytoreduction in patients with FIGO stage IIIC to IV ovarian, fallopian and peritoneal cancer in day-to day practice. A retrospective French multicentric study. Int J Gynecol Cancer 2012; 22: 1337-1343.
29. Wright JD, Lewin SN, Deutsch I et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 2011; 123: 467-473.
30. Wright JD, Herzog TJ, Neugut AI et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 2012; 120: 871-881.
31. Thrall MM, GoffBA, Symons RG et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011; 118: 537-547.
32. Aletti GD, Santillan A, Eisenhauer EL et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007; 107: 99-106.
33. Bristow RE, Zahurak ML, Dias-Montes TP et al. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related shortterm outcomes. Gynecol Oncol 2009; 115: 334-338.
34. Aletti CD, Eisenhauer EL, Santillan A et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 2011; 120: 23-28.